Dechra Pharmaceuticals In Tri-Solfen Deal, Ups Medical Ethics Stake
Mon, 8th Feb 2021 08:41
(Alliance News) -Â Dechra Pharmaceuticals PLC on Monday said it has secured the rights to market Tri-Solfen in Australia and New Zealand, and has acquired a further 1.5% stake in Medical Ethics Pty Ltd for AUD32.5 million, equivalent to around GBP18.1 million.
Under the deal, Dechra will acquire the marketing authorisations and enter a long term licensing agreement with Animal Ethics Pty Ltd. This will provide Dechra with exclusive rights to sell and market Animal Ethic s product, Tri-Solfen, which is already registered for sheep and cattle and is sold in Australia and New Zealand with current annual sales of AUD9.1 million.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;